The NIMH matrics initiative: Development of a Consensus Cognitive Battery

Robert S. Kern, Michael F. Green, Stephen R. Marder

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A key obstacle to the development of new drugs to treat the cognitive deficits of schizophrenia was the absence of a standard by which to measure their efficacy. Before granting approval for any new drug for this condition, the US Food and Drug Administration wanted a standard cognitive endpoint based on a broad consensus-based method. To address this obstacle, the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) intiative oversaw a process to develop a consensus neurocognitive battery. Its development included a ten-step process that is described in this article.

Original languageEnglish
Pages (from-to)173-186
Number of pages14
JournalProgress in Neurotherapeutics and Neuropsychopharmacology
Issue number1
StatePublished - Mar 2007
Externally publishedYes


  • cognition
  • schizophrenia
  • tests and measurement


Dive into the research topics of 'The NIMH matrics initiative: Development of a Consensus Cognitive Battery'. Together they form a unique fingerprint.

Cite this